DAC linker raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
=== Adverse effects === The most common side effects include too high or too low blood calcium levels, which can lead to headache, diarrhea, vomiting, paraesthesia (unusual sensations like pins and needles), hypoaesthesia (reduced sense of touch), and high calcium levels in the urine. In the US, the FDA label for parathyroid hormone contains a black box warning for osteosarcoma (a malignant bone tumor).
Wolverine's primary mutant power is an accelerated healing process, typically referred to as his mutant "healing factor", that regenerates damaged or destroyed tissues of his body far beyond that of normal humans. In addition to accelerated healing of physical traumas, Wolverine's healing factor makes him extraordinarily resistant to diseases, drugs and toxins. As a result of this ability, Wolverine has the appearance of a man in his early forties, although he is more than 100 years old. Wolverine's healing factor also affects a number of his physical attributes by increasing them to superhuman levels. His stamina is sufficiently heightened to the point that he can exert himself for hours. Wolverine's agility and reflexes are also enhanced to levels that are beyond the physical limits of the finest human athlete. Due to his healing factor's constant regenerative qualities, he can push his muscles beyond the limits of the human body without injury. Wolverine also has superhuman strength. The Muramasa blade, a katana of mystic origins that can inflict wounds that nullify superhuman healing factors, can suppress Wolverine's powers. Wolverine's senses of sight, smell, and hearing are super-humanly acute. He can see with perfect clarity at greater distances than an ordinary human, even in near-total darkness. His hearing is enhanced in a similar manner, allowing him to hear sounds ordinary humans cannot and hear across greater distances; he can hear the heartbeats of hostile living beings before conflict begins.
Post-translational modifications (PTMs) are covalent modifications to proteins. Like RNA splicing, they help to significantly diversify the proteome. These modifications are usually catalyzed by enzymes. Additionally, processes like covalent additions to amino acid side chain residues can often be reversed by other enzymes. However, some, like the proteolytic cleavage of the protein backbone, are irreversible. PTMs play many important roles in the cell. For example, phosphorylation is primarily involved in activating and deactivating proteins and in signaling pathways. PTMs are involved in transcriptional regulation: an important function of acetylation and methylation is histone tail modification, which alters how accessible DNA is for transcription. They can also be seen in the immune system, where glycosylation plays a key role. One type of PTM can initiate another type of PTM, as can be seen in how ubiquitination tags proteins for degradation through proteolysis. Proteolysis, other than being involved in breaking down proteins, is also important in activating and deactivating them, and in regulating biological processes such as DNA transcription and cell death.
=== Cytoplasmic condensates === Lewy bodies Stress granule P-body Germline P-granules – oskar Starch granules Glycogen granules Frodosomes (Dact1) Corneal lens formation and cataracts Other cytoplasmic inclusions such as pigment granules or cytoplasmic crystals Purinosomes Misfolded protein aggregation such as amyloid fibrils or mutant Haemoglobin S (HbS) fibres in sickle cell disease Signalosomes, such as the supramolecular assemblies in the Wnt signaling pathway. It can also be argued that cytoskeletal filaments form by a polymerisation process similar to phase separation, except ordered into filamentous networks instead of amorphous droplets or granules. Bacteria Ribonucleoprotein Bodies (BR-bodies)- In recent studies it has been shown that bacteria RNA degradosomes can assemble into phase-separated structures, termed bacterial ribonucleoprotein bodies (BR-bodies), with many analogous properties to eukaryotic processing bodies (P-bodies) and stress granules. FLOE1 granules: FLOE1 is a prion-like seed-specific protein that controls plant seed germination via phase separation into biomolecular condensates. Perinuclear compartment
=== Formylation reactions in purine biosynthesis === Two formylation reactions are required in the eleven step de novo synthesis of inosine monophosphate (IMP), the precursor of the purine ribonucleotides AMP and GMP. Glycinamide ribonucleotide (GAR) transformylase catalyzes the formylation of GAR to formylglycinamidine ribotide (FGAR) in the fourth reaction of the pathway. In the penultimate step of de novo purine biosynthesis, 5-aminoimidazole-4-carboxyamide ribotide (AICAR) is formylated to 5-formaminoimidazole-4-carboxamide ribotide (FAICAR) by AICAR transformylase.
Sources: en.wikipedia.org
Together with supplemental equations (for example, conservation of mass) and well-formulated boundary conditions, the Navier–Stokes equations seem to model fluid motion accurately; even turbulent flows seem (on average) to agree with real world observations. The Navier–Stokes equations assume that the fluid being studied is a continuum (it is infinitely divisible and not composed of particles such as atoms or molecules), and is not moving at relativistic velocities. At very small scales or under extreme conditions, real fluids made out of discrete molecules will produce results different from the continuous fluids modeled by the Navier–Stokes equations. For example, capillarity of internal layers in fluids appears for flow with high gradients. For large Knudsen number of the problem, the Boltzmann equation may be a suitable replacement. Failing that, one may have to resort to molecular dynamics or various hybrid methods. Another limitation is simply the complicated nature of the equations. Time-tested formulations exist for common fluid families, but the application of the Navier–Stokes equations to less common families tends to result in very complicated formulations and often to open research problems. For this reason, these equations are usually written for Newtonian fluids where the viscosity model is linear; truly general models for the flow of other kinds of fluids (such as blood) do not exist.
"wildly violating the sovereignty of Venezuela" by calling it a "high-handedness act", stating "The incident is another example that clearly confirms once again the rogue and brutal nature of the U.S., which the international community has so frequently witnessed for a long time". It added that North Korea "strongly denounces the U.S. hegemony-seeking act committed in Venezuela as the most serious form of encroachment of sovereignty and as a wanton violation of the U.N. Charter and international laws". It also called on the international community to recognize the "catastrophic" situation in Venezuela and denounce the U.S.'s "habituated violation of sovereignty of other countries". South Korea: On 3 January, President Lee Jae Myung instructed officials to ensure the protection of South Korean nationals in Venezuela and to prepare evacuation plans in case the situation worsens. The Ministry of Foreign Affairs set up a task force to protect its nationals. On 4 January, The Ministry of Foreign Affairs spokesperson urged "all parties to make every effort to ease tensions in the region" and hoped "that democracy will be restored with the will of the Venezuelan people respected and that the situation in Venezuela will be stabilised at an early date through dialogue". Malaysia: The Ministry of Foreign Affairs reaffirmed its position of "opposing all forms of foreign intervention in the internal affairs of sovereign states, as well as the threat or use of force".
== Distribution == Despite the name, none of the Periplaneta species is native to the Americas; P. americana was introduced to what is now the United States from Africa as early as 1625. They are now common in tropical climates because human activity has extended the insects' range of habitation, and are virtually cosmopolitan in distribution as a result of global commerce.
This does not replace the refrigeration system but facilitates cooling down of the external machinery. Containers stowed on the exposed upper deck are air-cooled, while those under deck are water-cooled. The water cooling design allows additional refrigerated containers under deck, as water can be used to dissipate the high amount of heat they generate. This system draws fresh water from the ship's water supply, which in turn transfers the heat through heat exchangers to the abundantly available sea water.
Sources: en.wikipedia.org
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019. Jennette's research focuses on understanding the causes of kidney diseases, particularly those induced by inflammatory and immunologic mechanisms, and improving the diagnosis and treatment of these diseases. He has authored and edited books, book chapters and articles in medical journals, and is an editor of four editions of the nephropathology textbook titled Heptinstall's Pathology of the Kidney. He has more than 25 named lectureships including the UNC School of Medicine 2015 Norma Berryhill Distinguished Lecture. He is the recipient of the Order of the Long Leaf Pine Award from the Governor of North Carolina for exemplary service to the State, Distinguished Service Award of the Association of Pathology Chairs, UNC Medical Alumni Distinguished Faculty Award, and Robert H. Heptinstall Lifetime Achievement Award from the Renal Pathology Society. Jennette served as the founding Secretary Treasurer of the Renal Pathology Society from 1993 until 1998, was elected vice president in 2003, and became president in 2004. He also served as President of the Association of Pathology Chairs from 2008 until 2010.
C6H4(CO)2NR + N2H4 → C6H4(CO)2N2H2 + RNH2 Alkyl amines can also be used. Some examples of phthalimide-containing drugs include thalidomide, amphotalide, taltrimide, talmetoprim, and apremilast. With a trichloromethylthio substituent, a phthalimide-derived fungicide is Folpet.
== Stereochemistry == Citalopram has one stereocenter, to which a 4-fluoro phenyl group and an N, N-dimethyl-3-aminopropyl group bind. As a result of this chirality, the molecule exists in (two) enantiomeric forms (mirror images). They are termed S-(+)-citalopram and R-(–)-citalopram.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.